Psagot Value Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Psagot Value Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12	Closed	-$1K	–	349
2022 Q2	$1K	Hold	12	–	–	﹤0.01%	290
2022 Q1	$1K	Buy	+12	New	+$1K	﹤0.01%	321
2021 Q1	–	Sell	-118	Closed	-$10K	–	365
2020 Q4	$10K	Hold	118	–	–	﹤0.01%	331
2020 Q3	$9K	Hold	118	–	–	﹤0.01%	374
2020 Q2	$15K	Hold	118	–	–	﹤0.01%	344
2020 Q1	$10K	Buy	+118	New	+$10.2K	﹤0.01%	351

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Psagot Value Holdings's BMRN Position: Q3 2022 in Review

Psagot Value Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 12 shares — an estimated $1K sold.

Psagot Value Holdings first reported a position in BMRN in Q1 2020 and held it in 6 quarters. The position peaked at $15K in Q2 2020. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Psagot Value Holdings reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Psagot Value Holdings sold 12 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1K.
Psagot Value Holdings first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Psagot Value Holdings's BioMarin Pharmaceuticals position peaked at $15K in Q2 2020.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Psagot Value Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.